Impact of CErebral Endovascular PROcedures on the Systemic Immune responSe Response
Trial Parameters
Brief Summary
In our ICU, it could notice that patients with cerebral arterio-venous malformation (AVM) treated with embolization develop more severe Ventilator Associated Pneumoniae (VAP) compare to other patients hospitalized for neurological diseases. The Dimethylsulfoxyde (DMSO), the solvent of the embolization implant, is known to have immune effect on vitro analysis. The investigator want to prove that exposition to embolization implant for a cerebral AMV modify the cytokines production involved the system immune's regulation.
Eligibility Criteria
Inclusion Criteria: * Adult hospitalized for a planned cerebral embolization Exclusion Criteria: * Immunosuppressed patient or immunosuppressive treatment (corticosteroid included) * Patient with auto-immune disease * Hospitalization in ICU or for a planned or emergency surgery in the past three months * Hospitalization for an active infection in the past three months * Pregnancy * Patients requiring steroid therapy to prevent postoperative nausea and/or vomiting